UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 25

Sortiert nach

Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury

Cancer immunology research, 2015-11, Vol.3 (11), p.1248-1256

2015

Volltextzugriff (PDF)

A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease

Blood, 2007-05, Vol.109 (10), p.4557-4563

2007

Volltextzugriff (PDF)

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis

Gastroenterology (New York, N.Y. 1943), 2019-07, Vol.157 (1), p.227-241.e7

2019

Volltextzugriff (PDF)

Construction and Immunogenicity Testing of Whole Recombinant Yeast-Based T-Cell Vaccines

Methods in molecular biology (Clifton, N.J.), 2016-01, Vol.1404, p.529

2016

Volltextzugriff (PDF)

Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis

Cancer Immunology, Immunotherapy, 2014-12, Vol.63 (12), p.1307-1317

2014

Volltextzugriff (PDF)

Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins

Vaccine, 2007-02, Vol.25 (8), p.1452-1463

2007

Volltextzugriff (PDF)

A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer

Journal of pancreatic cancer, 2021-03, Vol.7 (1), p.8-19

2021

Volltextzugriff (PDF)

Mutation-selective tumor remission with ras-targeted, whole yeast-based immunotherapy

Cancer research (Chicago, Ill.), 2004-08, Vol.64 (15), p.5084-5088

2004

Volltextzugriff (PDF)

Yeasts encoding tumour antigens in cancer immunotherapy

Expert opinion on biological therapy, 2005-04, Vol.5 (4), p.565-575

2005

Volltextzugriff (PDF)

Abstract 4509: Targeting tumor-derived exosomes using a lectin affinity hemofiltration device

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4509-4509

2020

Volltextzugriff (PDF)

Abstract A28: Immune responses to mutated Ras - development of a yeast-based immunotherapeutic

Molecular cancer research, 2014-12, Vol.12 (12_Supplement), p.A28-A28

2014

Volltextzugriff (PDF)

NCI experience using yeast-brachyury vaccine (GI-6301) in patients (pts) with advanced chordoma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.3081-3081

2014

Volltextzugriff (PDF)

A phase I study of a yeast-based therapeutic cancer vaccine, GI-6301, targeting brachyury in patients with metastatic carcinoma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e14026-e14026

2014

Volltextzugriff (PDF)

Abstract 5314: A proteomic signature predicts response to a therapeutic vaccine in pancreas cancer; analysis from the GI-4000-02 trial

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.5314-5314

2014

Volltextzugriff (PDF)

A pilot trial of a combination of therapeutic vaccines (GI-4000 and GI-6207) as adjunctive therapy with first-line therapy with bevacizumab plus either FOLFOX or FOLFIRI in stage IV patients with newly diagnosed Ras-mutant positive or negative metastatic colorectal cancer

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.TPS3638-TPS3638

2012

Volltextzugriff (PDF)

Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301)

Journal for immunotherapy of cancer, 2014-11, Vol.2 (S3), p.P148-P148, Article P148

2014

Volltextzugriff (PDF)

A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Commentary

Blood, 2007, Vol.109 (10)

2007

Volltextzugriff (PDF)

The kallikrein/kinin system and kinin antagonists in trauma

Immunopharmacology, 1996-06, Vol.33 (1-3), p.279-283

Rodell, Timothy C.

1996

Volltextzugriff (PDF)

THE DEVELOPMENT OF BRADYCORTM (CP-0127), A NOVEL BRADYKININ ANTAGONIST, IN SHOCK AND SEPSIS

Shock (Augusta, Ga.), 1995-12, Vol.4 (Supplement), p.19

1995

Volltextzugriff (PDF)

192 RISK PREDICTION IN RECENT CLINICAL TRIALS IN SEPSIS/SIRS: LESSONS LEARNED AND FUTURE DIRECTIONS

Shock (Augusta, Ga.), 1995-05, Vol.3 (5), p.59

1995

Volltextzugriff (PDF)

EFFECTS OF CP-0127, A BRADYKININ ANTAGONIST IN CLINICAL CONDITIONS ASSOCIATED WITH SYSTEMIC INFLAMMATION: 8

Shock (Augusta, Ga.), 1994-09, Vol.2 (Supplement), p.16

1994

Volltextzugriff (PDF)

Pulmonary oxygen toxicity and ischemia-reperfusion injury. A mechanism in common involving xanthine oxidase and neutrophils

The American review of respiratory disease, 1987-08, Vol.136 (2), p.483

1987

Volltextzugriff (PDF)

Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B

Journal of hepatology, 2016-09, Vol.65 (3), p.509-516

2016

Volltextzugriff (PDF)

Wilms' tumor-aniridia association: segregation of affected chromosome in somatic cell hybrids, identification of cell surface antigen associated with deleted area, and regional mapping of c-Ha-ras-1 oncogene, insulin gene, and beta-globin gene

Somatic cell and molecular genetics, 1984-09, Vol.10 (5), p.455-464

1984

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury

A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis

Construction and Immunogenicity Testing of Whole Recombinant Yeast-Based T-Cell Vaccines

Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis

Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins

A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer

Mutation-selective tumor remission with ras-targeted, whole yeast-based immunotherapy

Yeasts encoding tumour antigens in cancer immunotherapy

Abstract 4509: Targeting tumor-derived exosomes using a lectin affinity hemofiltration device

Abstract A28: Immune responses to mutated Ras - development of a yeast-based immunotherapeutic

NCI experience using yeast-brachyury vaccine (GI-6301) in patients (pts) with advanced chordoma

A phase I study of a yeast-based therapeutic cancer vaccine, GI-6301, targeting brachyury in patients with metastatic carcinoma

Abstract 5314: A proteomic signature predicts response to a therapeutic vaccine in pancreas cancer; analysis from the GI-4000-02 trial

A pilot trial of a combination of therapeutic vaccines (GI-4000 and GI-6207) as adjunctive therapy with first-line therapy with bevacizumab plus either FOLFOX or FOLFIRI in stage IV patients with newly diagnosed Ras-mutant positive or negative metastatic colorectal cancer

A randomized, placebo-controlled, double blind, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gem versus gem alone in patients with resected pancreas cancer with activating RAS mutations/survival and immunology analysis of the R1 subgroup

Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301)

A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Commentary

The kallikrein/kinin system and kinin antagonists in trauma

THE DEVELOPMENT OF BRADYCORTM (CP-0127), A NOVEL BRADYKININ ANTAGONIST, IN SHOCK AND SEPSIS

192 RISK PREDICTION IN RECENT CLINICAL TRIALS IN SEPSIS/SIRS: LESSONS LEARNED AND FUTURE DIRECTIONS

EFFECTS OF CP-0127, A BRADYKININ ANTAGONIST IN CLINICAL CONDITIONS ASSOCIATED WITH SYSTEMIC INFLAMMATION: 8

Pulmonary oxygen toxicity and ischemia-reperfusion injury. A mechanism in common involving xanthine oxidase and neutrophils

Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B

Wilms' tumor-aniridia association: segregation of affected chromosome in somatic cell hybrids, identification of cell surface antigen associated with deleted area, and regional mapping of c-Ha-ras-1 oncogene, insulin gene, and beta-globin gene

Suchergebnisse filtern